InvestorsHub Logo
Followers 3
Posts 349
Boards Moderated 0
Alias Born 08/26/2015

Re: None

Friday, 06/30/2017 9:34:14 AM

Friday, June 30, 2017 9:34:14 AM

Post# of 36216
This is what I understand from the latest PR:
http://www.marketwired.com/press-release/lifeline-biotechnologies-updates-pinksheets-llbo-2224617.htm

- Our stake in Cyrcadia Inc in now 45%, so LLBO should rise to a minimum of $0.0045

Lifeline's ownership is increased to over 45% of Cyrcadia, Inc., making Lifeline Cyrcadia, Inc.'s largest single shareholder.



- Now is Cyrcadia Asia that will own the mobile technology that will be licensed to Cyrcadia Inc.

Cyrcadia Asia Limited will license Cyrcadia, Inc. for the developed Bluetooth™ and additional sensors products once development is completed



- Cyrcadia Inc has raised money at $1/share

Cyrcadia, Inc. received the following compensation for the license to Cyrcadia Asia Limited: An $830,000 Cyrcadia, Inc. equity investment at $1.00 per share with an equal $1.00 warrant; a $1,050,000 promissory note



- Cyrcadia Inc has now a stake of Cyrcadia Asia not specified, which means that we also own nearly 50% of that stake.

Cyrcadia, Inc. received an equity interest in Cyrcadia Asia, Limited.



- Cyrcadia Asia will pay for part of the annual administrative costs of Cyrcadia / going forward?.

Additionally, Cyrcadia Asia Limited assumed approximately $500,000 of Cyracdia, Inc.'s annual general and administrative expenses.



- The iTbra will have new sensors that locate the cancer cells. This is a great improvement because mammography in dense tissue are blind

The added sensors will enable the systems to exactly locate the tissue abnormality or cancer within the breast tissue.



- The trial is not completed but results are great.

Preliminary indications suggest, test-patient wear time could be reduced to two hour (2) vs the 24 hour wear time at the commencement of the trials. Additionally, the preliminary results have indicated a probable 84% accuracy and sensitivity, specificity at 75%



- Cyrcadia Inc has not yet applied for FDA Class I and CE Mark clearance

Cyrcadia, Inc. expects to apply for FDA Clearance and a CE Mark, (to market in the European Union and Asian markets)



- The sales in the US and Europe should start Q42017 or Q12018, possibly through hospital using the current FDA clearance and waiting for the OTC Class I approval.

with anticipation of launching its technology to market possibly in late 2017 or early 2018.



- The Detected movie may not be finished

Cisco Systems, Inc. is financially supporting the filming of a documentary by Ironbound Films called "Detected Movie" about the evolution of Cyrcadia, Inc.'s technology.



- Now the LLBO value is directly linked to the Cyrcadia Inc milestones and the price at which they raise future money.

Currently, Lifeline's current market cap is over twelve million dollars ($12,000,000). The current value is projected to grow with Cyrcadia, Inc.'s future achievements.



JMO


Disclaimer: This information is only my opinion and should not be considered as an advice or a recommendation to investors or potential investors in relation to holding, purchasing or selling securities or other financial products or instruments.